Back to Feed
ClinicalTrials.gov|Clinical Trial
This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
iRegene Therapeutics Co., Ltd.
Abstract
This is a phase 1/2 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease. Phase: PHASE1, PHASE2 Status: RECRUITING Conditions: Parkinson Disease Interventions: Human Dopaminergic Progenitor Cells
Keywords
Parkinson Disease